As Legend Biotech and Johnson & Johnson’s multiple myeloma cell therapy prospect nears the FDA finish line, the companies are moving to carve out a manufacturing …

As Horizon Therapeutics’ one-and-a-half-year-old thyroid eye disease med Tepezza starts to spread its wings, the drugmaker is standing up in-house manufacturing to help blunt any further …

As Bristol Myers Squibb looks to guard Celgene’s top-selling cancer drug Revlimid from copycat competition, the company has inked a series of deals to welcome …

Amgen’s high-profile PCSK9 patent fight with Sanofi and Regeneron has attracted a who’s who of biopharma observers over the years, with many top companies voicing support for each side. Now, Amgen …

In rapidly developing a COVID-19 vaccine—and a highly effective one at that—Novavax got the hard part right. But the logistics of manufacturing the vaccine has proven …

For three years, Merck & Co.’s Keytruda has been the onlyimmuno-oncology drug allowed to treat cervical cancer. Now, thanks to a new clinical win, Merck aims to …

Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year …

Despite back-to-back phase 3 trial wins in atopic dermatitis, Incyte’s ruxolitinib cream isn’t immune to class-wide JAK inhibitor safety scrutiny.  Incyte on Friday disclosed that the FDA has put off …

Bayer, currently in the midst of a gung-ho cell therapy expansion in the U.S., is turning its attention back to Europe as it looks to …

When Eli Lilly last month revealed that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing facility in Branchburg, New Jersey, the …